StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Etodolac

HCID 3308
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
41340-25-4
Standard-SMILES
CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
InChIKey
NNYBQONXHNTVIJ-UHFFFAOYSA-N
Summenformel
C17H21NO3
Durchschnittliche Molmasse
287,35 g/mol
Monoisotopische Masse
287,15214353

Überblick

Etodolac can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements.

Namen und Bezeichner

Bevorzugter Name
Etodolac
IUPAC
2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
Englischer Name
Etodolac
Summenformel
C17H21NO3
Molmasse
287.35

Namen und Synonyme

etodolac41340-25-4Etodolic acidLodineUltradolLodine XLEdolanRamodarEtodolacoZedolacAY-24236Etodolacum
Weitere Namen anzeigen
HypenEtopenRAK-591OstelucEtodineay24236
FlancoxTedolanAY 24236AY-24,236EccoxolacNapilacLodin xl1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid

Datenbank-Bezeichner

CAS
41340-25-4
PubChem CID
3308
DTXSID
DTXSID9020615
ChEMBL
CHEMBL622
ChEBI
CHEBI:4909
UNII
2M36281008
EC Number
629-689-1
Nikkaji
J16.541G

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2,8
Polarare Oberfläche (TPSA)
62,3 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
4
Schwere Atome
21
Formalladung
0
Komplexität
399

Experimentelle und physikochemische Eigenschaften

Drugs · 3 Einträge

DEA NFLIS-Drug Category -> Analgesics

Pharmaceuticals

Pharmaceuticals -> Used in Switzerland

LogP · 2 Einträge

2.5

2.75

Solubility3.92e-02 g/L
Human Drugs · 4 Einträge

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Animal DrugsActive Ingredients (Etodolac) -> FDA Greenbook
Melting Point145 - 148 °C
Physical DescriptionSolid
Dissociation Constants4.65
Collision Cross Section · 2 Einträge

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P264+P265, P270, P280, P301+P316, P305+P351+P338, P318, P321, P330, P337+P317, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 50 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

Hazard Traits - Developmental Toxicity; Reproductive Toxicity

Etodolac: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Prospective studies show that 1% to 2% of patients taking etodolac experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (greater than 3 fold elevated) occur in less than 1% of patients.

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Etodolac

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding> 99% bound, primarily to albumin
Pharmacodynamics · 1 Eintrag

Etodolac is an anti-inflammatory agent with analgesic and antipyretic properties. It is used to treat osteoarthritis, rheumatoid arthritis and control acute pain. The therapeutic effects of etodolac are achieved via inhibition of the synthesis of prostaglandins involved in fever, pain, swelling and inflammation. Etodolac is administered as a racemate. As with other NSAIDs, the S-form has been shown to be active while the R-form is inactive. Both enantiomers are stable and there is no evidence of R- to S- conversion _in vivo_.

Mechanism of Action · 1 Eintrag

Similar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5 – 50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.

Biological Half-LifeTerminal t<sub>1/2</sub>, 7.3 &plusmn; 4.0 hours. Distribution t<sub>1/2</sub>, 0.71 &plusmn; 0.50 hours
Metabolism/Metabolites · 2 Einträge

Etodolac is extensively metabolized in the liver. Renal elimination of etodolac and its metabolites is the primary route of excretion (72%). Metabolites found in urine (with percents of the administered dose) are: unchanged etodolac (1%), etodolac glucuronide (13%), hydroxylated metabolites (6-, 7-, and 8-OH; 5%), hydroxylated metabolite glucuronides (20%), and unidentified metabolites (33%). Fecal excretion accounts for 16% of its elimination.

Zugehörige Reaktionen

14
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 98464
HRID 98464als Edukt
Reaktionsgleichung von HRID 268678
HRID 268678als Edukt
Reaktionsgleichung von HRID 268680
HRID 268680als Edukt
Reaktionsgleichung von HRID 834395
HRID 834395als Produktals Edukt
Reaktionsgleichung von HRID 838763
HRID 838763als Edukt
Reaktionsgleichung von HRID 901055
HRID 901055als Edukt
Reaktionsgleichung von HRID 945126
HRID 945126als Produktals Edukt
Reaktionsgleichung von HRID 946786
HRID 946786als Produktals Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

164.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

163.36 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
145 · 145-1480C
Siedepunkt
507.9 · 507.9±45.0 °C(Predicted)
Dichte
1.193 · 1.193±0.06 g/cm3(Predicted)
storage temp.
2 · 2-8°C
Löslichkeit
Practically insoluble in water, freely soluble in acetone and in ethanol (96 per cent)
Aggregatzustand
Solid
pka
4.65 · 4.65(at 25℃)
Farbe
White to Orange to Green
Wasserlöslichkeit
40 mg/L · 40mg/L(37 ºC)
Merck
14 · 14,3874
BCS Class
2 · 2
Major Application
pharmaceutical (small molecule)
InChI
1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
InChIKey
NNYBQONXHNTVIJ-QGZVFWFLSA-N
SMILES
CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12
CAS Datenbank
41340 · 41340-25-4(CAS DataBase Reference)
EPA chemische Informationen
3 · Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro- (41340-25-4)
· 2 Einträge

◉ Summary of Use during Lactation

◈ What is etodolac?

Sicherheitsdaten

wgk
3
ridadr
3249
hs_code
2934999090
RTECS-Nr.
UQ0360000
risk_code
23/24/25-40-36-25-36/37/38
hazard_code
T,Xi
safety_code
22-36-45-26-36/37
hazard_class
6.1(b)
packing_group
III
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Acute Tox. 3 Oral

Etodolac has known human metabolites that include (2S,3S,4S,5R)-6-[2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid.

FDA Pharmacological Classification · 6 Einträge

2M36281008

ETODOLAC

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Etodolac is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of etodolac is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

A subclass of cyclooxygenase inhibitors with specificity for CYCLOOXYGENASE-2.

Absorption, Distribution and Excretion · 4 Einträge

Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.

It is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected. Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite.

390 mL/kg

Oral cl=49.1 mL/h/kg [Normal healthy adults]

Cellular LocationsCytoplasm
Metabolite PathwaysEtodolac Action Pathway

Verwendung und Herstellung

UsesUse (kg) in USA (2002): 25800
Use Classification · 2 Einträge

Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients

Pharmaceuticals

Anwendungen · 2 Einträge

BeschreibungEtodolac (etodolic acid) is a non-steroidal antiinflammatory/analgesic agent useful in the treatment of various inflammatory conditions, including rheumatoid and osteoarthritis.

VerwendenEtodolac is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Etodolac displays anti-inflammatory effects in both adjuvant arthritic and normal rats. E todolac is an anti-inflammatory; analgesic.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

ChloralhydratEthyl-3-oxovalerat2-EthylanilinLithium Aluminum HydrideOxalyldichloridIndol7-Ethyl tryptopholRAK 593S-EtodolacMethyl-3-oxovalerat
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.